Alberta launches remote communication between patients and providers as part of COVID-19 response
CALGARY, AB, July 24, 2020 /CNW/ - The Government of Alberta has given patients the ability to create their own secure messaging account to connect with healthcare providers. Brightsquid Secure-Mail has been integrated into the provincial MyHealth Records (MHR) portal. Patients registered for MHR can create their own Secure-Mail account to communicate virtually with community healthcare providers.
When the pandemic imposed restrictions on physical interaction, the healthcare system needed new ways to deliver care. Alberta responded with a solution that keeps patients in contact with their community healthcare providers even at a distance.
"IMAGINE Citizens is very supportive of actions that enable patients to have more access to and involvement in creating and monitoring their own health records. A secure mail function is an important component," says Judy Birdsell, Founder and Board Chair of IMAGINE Citizens Collaborating for Health.
"Thousands of Albertans now have two-way digital communication with any subscribing health clinic, and it's connected to their personal health record," said Rohit Joshi, Co-Founder and CEO of Brightsquid. "We're pleased to offer our expertise in our home province to help address the communication concerns raised by the pandemic and prepare Alberta for the future of healthcare."
Patients and clinics in Alberta now use Secure-Mail to exchange over 50,000 messages each month. There is no cost to patients using Secure-Mail, and Secure-Mail is available at no cost to clinics for their first 2 months. Clinics can subscribe to Brightsquid at Brightsquid.com. Patients can learn more about creating and connecting their accounts here.
About MyHealth Records:
MyHealth Records is a patient-centred online tool that lets most Albertans see and keep track of their health information in one secure place. Albertans can view their immunizations, medications, some commonly ordered lab results including COVID-19 test results, and communicate with community care providers using Secure-Mail.
IMAGINE Citizens is an independent, citizen led society in Alberta whose mission is to enable and mobilize citizens' ability to influence, and become valued partners in improving health care experiences and outcomes for all.
About Brightsquid Secure Communications Corp.:
Brightsquid Secure-Mail is a proven secure email service that has delivered almost 2 Million messages. It simplifies communication between patients and their healthcare providers to accelerate care, increase access and create clinic efficiencies that benefit the entire healthcare system.
SOURCE Brightsquid Secure Communications Corp.
Avicanna announces the award of two Canadian government NSERC grants: 1) Cannabinoid-based pharmaceutical formulations for the treatment of COVID-19 in collaboration with the University of Toronto; and, 2) Evaluation of cannabinoids for reversing cannabis-based toxicosis in collaboration with the University of Guelph
In addition to a recent MITACS award, Dr. Christine Allen, a Professor at the University of Toronto, was awarded an NSERC Alliance grant for development of cannabinoid-based pharmaceutical formulations for the treatment of COVID-19 induced lung inflammation
Avicanna further expands its existing neurobiological research collaboration with Dr. Jibran Khokhar, a Professor at the University of Guelph, with a 2-year NSERC Alliance grant to investigate the neural basis of cannabis-induced toxicosis
The two NSERC grants leverage the proven track record of Avicanna, the University of Toronto and the University of Guelph in the research and clinical development of cannabinoid-based medicines
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/
TORONTO, July 24, 2020 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that the Company's research collaborators have received two independent peer-reviewed grants from the Natural Sciences and Engineering Research Council of Canada ("NSERC"). The NSERC Alliance grants will be used to expand the investigators' collaborative research with Avicanna.
For the past three years, Dr. Christine Allen's research group (CARG) in the Leslie Dan Faculty of Pharmacy at the University of Toronto has supported the development and optimization of Avicanna's cannabinoid-based products including commercial cosmetics (Pura H&W) and medical cannabis (Rho Phyto) product lines and the pharmaceutical pipeline that is currently under clinical investigation. Dr. Allen will now leverage a recent MITACS award in addition to this NSERC Alliance grant in collaboration with Avicanna to develop a cannabinoid-based formulation for treatment of COVID-19 related lung inflammation.
A second NSERC Alliance grant was awarded to Dr. Jibran Khokhar, Assistant Professor at the University of Guelph, who has an extensive track-record in behavioural pharmacology and neuroscience. Avicanna's research program with Dr. Khokhar focuses on evaluating a variety of cannabinoids in several preclinical models of human psychiatric conditions including mental health disorders such as anxiety, depression, and PTSD. The NSERC grant was awarded to evaluate the neurobiological underpinnings of cannabis toxicosis in a preclinical model, and test the potential efficacy of Avicanna's naturally-derived cannabinoids and formulations in the treatment of cannabis-induced toxicosis. With the recent changes in the Canadian regulations for Cannabis 2.0 allowing for cannabinoid edibles and vapes, there is concern around an increased risk for adverse events arising from accidental high-dose cannabis ingestion. Thus, this two-year project will determine the behavioural and neural correlations of cannabis-induced toxicosis and the effects of cannabinoids for counteracting cannabis-induced toxicosis.
Dr Jibran Khokhar, commented, "This research is extremely timely with the new Cannabis 2.0 regulations and the increased risk for cannabis-induced toxicosis. I am thankful to NSERC and Avicanna for support of this important research that will have an impact in our understanding of the neurobiological underpinnings of, and provide novel treatment avenues to treat, adverse events related to high-dose cannabis exposures."
About Avicanna Inc.
Avicanna is an Ontario, Canada based corporation focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products through its two main business segments, cultivation and research and development.
Avicanna's two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia are the base for Avicanna's cultivation activities. These two companies are licensed to cultivate and process cannabis for the production of cannabis extracts and purified cannabinoids including cannabidiol (CBD) and tetrahydrocannabinol (THC).
Avicanna's research and development business is primarily conducted out of Canada at its headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto. Avicanna's scientific team develops products, and Avicanna has also engaged the services of researchers at the Leslie Dan Faculty of Pharmacy at the University of Toronto for the purpose of optimizing and improving upon its products.
Avicanna's research and development and cultivation activities are focused on the development of its key products, including plant-derived cannabinoid pharmaceuticals, phyto-therapeutics, derma-cosmetics, and Extracts (defined as plant-derived cannabinoid extracts and purified cannabinoids, including distillates and isolates), with a goal of eventually having these products manufactured and distributed through various markets.
Stay Connected
For more information about Avicanna, visit www.avicanna.com, call 1-647-243-5283, or contact Setu Purohit, President by email info@avicanna.com.
Cautionary Note Regarding Forward-Looking Information and Statements
This news release contains "forward-looking information" within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, "may", "would", "could", "will", "likely", "expect", "anticipate", "believe, "intend", "plan", "forecast", "project", "estimate", "outlook" and other similar expressions, and includes statements with respect to the ability of the Company and CARG to develop cannabinoid-based pharmaceutical formulations to treat COVID-19 induced lung inflammation, the ability of the Company to develop cannabinoid-based pharmaceutical products, the results of the two-year project with the University of Guelph determining the behavioural and neural correlations of cannabis-induced toxicosis and the effect of cannabinoids to counteract cannabis-induced toxicosis. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management's experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits.
Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company's annual information form dated April 15, 2020, filed with the Canadian securities regulators and available under the Company's profile on SEDAR at www.sedar.com.
The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
SOURCE Avicanna Inc.
Scary Toxins Are Hiding in Your Household Cleaners and Beauty Products
Although reading the (usually incomplete) ingredient list on your products won’t 100 percent guarantee that you’re avoiding toxins, it can be helpful for avoiding the most common and most dangerous toxins.
Here’s a handy list of the most important ingredients to avoid—and tips on the common products that use them.
Parabens
These toxic chemicals, often found in household cleaners and beauty products, are preservatives: They prevent the growth of bacteria, yeast and mold in cosmetic products. They can appear in different forms, so watch out for:
Butylparaben
Isobutylparaben
Ethylparaben
Propylparaben
Methylparaben
Parabens are absorbed through your skin, and it’s believed (but not yet proven) that excessive use could lead to cancer. Parabens are xenoestrogens, which means they mimic estrogenic hormones in your body and can lead to the production of more estrogen. They can also affect your endocrine system, causing reproductive, immune, neurological and developmental issues. They can also lead to skin irritation and neurotoxicity.
Be sure to check any household products that claim to be antimicrobial or antifungal (such as dish soap, glass cleaner, all-purpose cleaner, bathroom cleaner and others); they probably contain parabens under the above-mentioned names—unless they use a nontoxic formulation.
Formaldehyde
Watch out for this dangerous ingredient, which is often used in packaged foods, nail polishes, beauty products, pressed wood furniture and household cleaning products. Formaldehyde can irritate your skin and aggravate asthma symptoms. It can even cause cancer if inhaled too often, and it is also easily absorbed by your skin.
Always use in a well-ventilated room—or try to avoid products containing Formaldehyde altogether. In addition to causing cancer, it can also cause watery eyes, skin irritation, nausea and respiratory irritations. Formaldehyde has several names; keep an eye out for any of these:
Formalin
Methanediol
Formic aldehyde
Methyl aldehyde
Methanal
Methylene oxide
Methylene glycol
Alcohol
You’ll find alcohol on many cosmetic and household labels. It may be refreshing on your warm skin and dry quickly, but alcohol can also irritate and dry out your skin. It’s especially dangerous for those with sensitive skin.
Using alcohol-based products constantly can result in your skin losing its protective barrier and making you more prone to viruses and bacteria. Look out for alcohol under its other names, including:
SD alcohol
Methanol
Isopropyl
Denatured ethyl alcohol
Ethanol
Phthalates
Phthalates are used in synthetic fragrances. You’ll find them in everything from laundry detergent and soap to cosmetics—and even toilet paper.
Phthalate exposure has been shown to cause early puberty in girls, which is a risk factor for breast cancer later in life. It also disrupts the endocrine system, affecting your body's most important functions, including metabolism, sleep and mood and tissue function. Best to avoid them!
International Self-Care Day 2020
OTTAWA, ON, July 24, 2020 /CNW/ - Today, we join communities across the world in celebrating International Self-Care Day. Self-care is all about the important role you play in your own health. Whether exercising, brushing your teeth, eating well, applying sunscreen, quitting smoking, or treating fevers and headaches, self-care is what we all do to stay healthy.
This day has served over the years as a great reminder for each of us to take care of ourselves and for our governments to support us in doing so. Yet, self-care is now more important than ever before.
As Canadians cared for themselves at home, including their efforts to prevent and treat COVID-19, they enabled our health care system to focus on critical cases of COVID-19 and emergencies. Self-care has been a critical part of our collective COVID-19 response. Based on a recently published survey, since the COVID-19 pandemic began, 39% of Canadians have been seeking more information about their health from home, 28% consider that their knowledge about their health has improved, and 58% of those who managed health conditions themselves during the pandemic were satisfied with their efforts.
This year, celebrate Self-Care Day by reflecting on the role self-care has played for each of us individually and all of us collectively during the COVID-19 pandemic, and by planning for our health and well-being in the future. Now more than ever, self-care benefits you and everyone around you.
More information on each of the seven pillars of self-care, recognised as a holistic approach to health worldwide, can be found at selfcare.ca. Share your tips and stories of self-care with #iselfcare across social media!
ABOUT INTERNATIONAL SELF-CARE DAY
International Self-Care Day is a worldwide campaign held annually on July 24th (7/24) as a reminder that the benefits of self-care are experienced 24 hours a day, seven days a week. It celebrates the importance of self-care and encourages the public to practice responsible self-care.
ABOUT CHP CANADA
CHP Canada is the industry association representing the companies making evidence-based over-the-counter medicines and natural health products. These are the products you can find in medicine cabinets in every Canadian home.
Dancing To The Darkest Light Aims To Inspire Others Who Are Navigating Challenging Times
Los Angeles, CA, July 24, 2020— Soheila Adelipour hopes you never look at life the same way after reading her memoir of survival, Dancing to the Darkest Light. Her story begins in Iran, where her family, desperate to escape the Islamic revolution, fled to New York. Her family found solid footing in the Big Apple, living the epitome of the American dream, until one day, all they had were nightmares. In a relatively short period of time, Adelipour lost a son and two siblings. Her book offers a riveting account of her healing process, and through her example of extraordinary resilience, she hopes to inspire others who are facing tragedy and heartbreak.
Chronicling their experiences in Dancing to the Darkest Light, Adelipour recounts how her only brother became a neurosurgeon while others followed different paths. But their successful relocation and the joy they felt over each triumph was soon shattered when Adelipour's second son, Stefan, was killed in a dorm room fire before his scheduled graduation from Boston University.
Adelipour channeled her grief into the foundation she established in his name. Soon after, her older sister had to undergo five brain surgeries that left her blind and deaf before ultimately claiming her life. The same week, their only brother who was supervising her care was diagnosed with leukemia. Adelipour gave him her bone marrow and 60 percent of her liver when his liver stopped functioning. Doctors ultimately announced he was cancer-free with a perfectly functioning liver, but the week he was to come home, he died from pneumonia.
How one perseveres under the weight of all this loss is at the core of Dancing to the Darkest Light. “When life plays different music, we have to be fluid and dance to the new tune,” Adelipour said.
Adelipour received her bachelor's degree in business and her master's degree in Art Gallery Management while her first two children were in diapers. She was involved with the World of Arts and Antiques in New York City and followed that by operating high-end gift stores.
Free Speech platform calls for transparency as Google faces allegations of Blacklisting
Las Vegas, Nevada – Parler, the People-driven social platform, is calling for Google to reveal information on its algorithmic search function and how the company selects what results to display.
Google made international headlines when conservative-leaning online publications like Breitbart and Drudge Report did not appear in search results for a two-hour period yesterday. The progressive site Occupy Democrats was also affected, while legacy media sites were not.
Company spokespeople called the incident a “glitch,” but former Google engineer Michael Wacker says that the incident indicates the existence of systemic backlisting of conservative sites by Google. Wacker argued that the search giant likely accidentally blocked them completely, while normally they only throttle or otherwise manipulate the search results to suppress their visibility.
Dr. Robert Epstein, a researcher and registered Democrat who has argued Google has the power to sway up to 10 percent of American voters in the 2020 election, agreed with the assessment. Epstein told Mediate, “It's likely that a person or algorithm at Google added 'breitbart.com' and other URLs to one or more of the company's blacklists. Then, perhaps after some pushback, someone pulled those URLs off the blacklists.”
Google controls over 86 percent of the global search market.
“The credible allegations that Google backlists sites that challenge their corporate agenda is chilling,” said Parler CEO John Matze. “Activists and critical thinkers on both sides of the aisle have long suspected Google of manipulating search results to obscure content, and this is further evidence of that behavior. The implications are huge and could even constitute illegal interference in our elections. Google should come clean and reveal their process for determining how content is displayed—who is making those choices and why those choices are made.”
Parler does not collect user data or algorithmically curate content. A user’s timeline consists (aside from sponsored ads) of posts from the users one follows, arranged chronologically. Tags operate in the same way. Content is never censored, throttled or blacklisted.
Parler was founded in 2018 and has 3.3 million users. The platform is committed to free speech, does not mine or sell user data, and does not censor content based on politics or ideology. Parler continues to stand with the People and against Technocronyism. ###
University sports centre to reopen on Saturday July 25
Phased return of classes fully compliant with social distancing and health and safety measures
22 July 2020 If ever there was a time to join a gym, a fitness class or take up a sport, it’s now - that’s the massage from trainers at the University of Bradford’s Unique fitness centre, which reopens on Saturday (July 25).The centre is ‘match ready’, with a new social distancing layout, contactless booking system and cleaning stations to comply with the latest health and safety guidance.Located in the heart of the city, the centre boasts the kind of facilities most others would be envious of, including a climbing wall, indoor football court, 11-a side outdoor pitch, tennis and squash courts, fitness centre, indoor spin room and more.During lockdown, some of these have been off limits but others, such as the outdoor 'pop up' gym, tennis and fitness classes have been running for several weeks.From July 25, there will be a phased approach to the reopening of facilities, beginning with the gym and pool.Widespread research indicates physical activity can boost mental health, while the Government is urging people to improve their fitness in general during the current pandemic. Now instructors are keen to get the word out to the residents of Bradford - and beyond - about what’s on offer.Sports Centre Manager Daniel Fawcett is enthusiastic about the possibilities for newcomers: “During lockdown, we have offered a lot of services not only to our member base but members of the community. “We opened our tennis courts towards the end of May, as that was approved by the government and we introduced personal training and outdoor fitness classes shortly after, which is free for members and for a small fee for others. “We’re keen to get the word out to people about the facilities we have here and the fact it’s really affordable compared to some other places. For example, students pay £14.50 a month, which is very competitive, considering no other facility in the heart of the city has a 25m pool.”The 36-year-old father of two, from Birkenshaw, says: “We are not just a gym, we’re more of a sports and fitness complex because we have all these additional facilities. A lot of people think that because we’re on campus it’s just for students and staff but we’re open to all.”Qualified personal trainers and fitness instructors are also on hand to advise anyone who joins and the atmosphere is friendly and non-judgemental, in line with the university’s wider policy on social inclusion.Daniel adds: “It’s never too late to join a gym or start your fitness journey. I remember doing that myself at a time in my life when I was overweight and then seeing the difference it made not just physically but mentally and in terms of gaining confidence.“One thing we’ve seen during lockdown is an emphasis on people’s mental health. Having a break from the home/life setting can work wonders. Our mantra is you’re not striving for perfection, you are striving to be better than you were the previous day. We all have to start somewhere and I see this period as the perfect time for that.” Contact them on 01274 234871 or email unique@bradford.ac.uk Picture 1) University of Bradford sports centre manager Daniel Fawcett. Other pictures show examples of the outdoor pop up gym.
(n)SPRAVATO® (esketamine)* Nasal Spray is Available for Canadian Patients
A New Antidepressant with a Novel Mechanism of Action to Treat Major Depressive Disorder in Adults
TORONTO, July 22, 2020 /CNW/ - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that SPRAVATO® (esketamine), following a Notice of Compliance (NOC) from Health Canada, is now available for Canadian patients. SPRAVATO® nasal spray, the first glutamate receptor modulator approved for the treatment of major depressive disorder (MDD), is indicated for use in combination with an oral antidepressant (that is either a SSRI or SNRI**) for the treatment of MDD in adults who have not responded adequately to at least two separate courses of treatment with different antidepressants, each of adequate dose and duration, in the current moderate to severe depressive episode.
MDD is a leading cause of disability worldwide1 and can have a profound impact on peoples' lives. In Canada, about 11 per cent of men and 16 per cent of women will experience major depression in the course of their lives.2 Although currently available antidepressants are effective for many patients, the symptoms of depression in up to one-third of patients do not adequately respond to treatment.3
"Depression is a common and debilitating condition that can have a substantial impact on the emotional and functional well-being of those living with the condition as well as their loved ones. The impact of depression is most significant for those who have gone through multiple treatments without relief," said Dr. Roumen Milev, Vice President, Medical and Academic Affairs, Providence Care Hospital and Director, Centre for Neuroscience Studies, Queen's University, Kingston, Ontario. "In clinical trials, we saw SPRAVATO® provide a sustained improvement in symptoms of major depressive disorder. This new therapy has the potential to change the treatment paradigm for patients and their physicians."
The global SPRAVATO® clinical development program included one Phase 2 (n=108) and five Phase 3 (n=1,601) clinical trials with more than 1,700 patients. Health Canada's approval was based on two pivotal Phase 3 clinical trials; a short-term induction study and a long-term maintenance study.4
In the induction study, those who took SPRAVATO® and an oral antidepressant experienced a statistically significant improvement in depression symptoms at four weeks compared to those who received a placebo and an oral antidepressant.
Patients who participated in the long-term maintenance study who were in stable remission and continued treatment with SPRAVATO®, were 51 per cent less likely to relapse versus those who maintained a regimen of a placebo and an oral antidepressant.
"Mood Disorders Society of Canada is pleased that a new treatment option is available for adults with major depressive disorder who have failed multiple previous treatments," said Dave Gallson, National Executive Director, MDSC. "With 227 unique combinations of symptoms for someone with depression, new options that work in novel ways are essential."
To support safe and responsible use, SPRAVATO® must be administered by the patient under the direct supervision of a healthcare professional and is only available to patients through physicians and pharmacists enrolled in a controlled distribution program called the JANSSEN JOURNEY™ Program.
About Major Depressive Disorder MDD is a complex mood disorder caused by various factors, including genetic predisposition, personality, stress and brain chemistry.5 It is characterized by symptoms of a persistently low mood, changes in appetite and sleep, fatigue, loss of motivation, or feelings of worthlessness.6 It can also be associated with a substantial loss in productivity, quality of life and increased mortality from suicide.7
MDD affects more than 264 million people of all ages, globally.8 Although currently available antidepressants are effective for many patients, about one-third of patients do not adequately respond to treatment.9
About the SPRAVATO® Clinical Trial Program SPRAVATO® nasal spray was evaluated for efficacy and safety in more than 1,700 adult patients (18 to 86 years) who met DSM–5 criteria for MDD and were non–responders to at least two oral antidepressants of adequate dosage and duration, in the current major depressive episode. The development program included five Phase 3 studies (three short-term and two long-term studies) and one Phase 2 dose-ranging study.10
In the Phase 3 program, the most commonly observed adverse reaction in patients treated with SPRAVATO® plus an oral antidepressant were dissociation (involving some degree of detachment from reality), dizziness, nausea, sedation, headache, vertigo, dysgeusia, hypoesthesia, increased blood pressure, anxiety and vomiting.11
About SPRAVATO® SPRAVATO® nasal spray in combination with an oral antidepressant (that is either a SSRI or SNRI**) is indicated for the treatment of MDD in adults who have not responded adequately to at least two separate courses of treatment with different antidepressants, each of adequate dose and duration, in the current moderate to severe depressive episode. SPRAVATO® works differently than currently available therapies for MDD. It works on the N-methyl-D-aspartate (NMDA) receptor, an ionotropic glutamate receptor in the brain, which is a different mechanism of action than existing antidepressants.
SPRAVATO® builds on Janssen's more than 50-plus-year history and commitment to research that makes a difference for people living with mental illnesses, including severe mood disorders.
SPRAVATO® is self-administered as a nasal spray, under the supervision of a healthcare professional and is absorbed through the lining of the nasal passages.12
About the Janssen Pharmaceutical Companies of Johnson & Johnson At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.
***Dr. Milev was not compensated for any media work. He has been compensated as a consultant.
**** Dave Gallson was not compensated for any media work. Mood Disorders Society of Canada has received funds for patient engagement.
Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding SPRAVATO®. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Inc., any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 29, 2019, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in the company's most recently filed Quarterly Report on Form 10-Q, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.
3 US National Library of Medicine. Pharmacological approaches to the challenge of treatment-resistant depression. Dialogues in clinical neuroscience. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4518696/.Accessed June 19, 2020
4 SPRAVATO® Product Monograph. Janssen Inc. Version date: May 19, 2020.
6 Lam RW, McIntosh D, Wang J, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 1. Disease Burden and Principles of Care. Can J Psychiatry. 2016;61(9):510-523
7 Bakish, D. The Journal of Clinical Psychiatry. New Standard of Depression Treatment: Remission and Full Recovery. J Clin Psychiatry. 2001;62 Suppl 26:5-9
9 US National Library of Medicine. Pharmacological approaches to the challenge of treatment-resistant depression. Dialogues in clinical neuroscience. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4518696/.Accessed June 19, 2020
10 SPRAVATO™ Product Monograph. Janssen Inc. Version date: May 19, 2020.
11 SPRAVATO™ Product Monograph. Janssen Inc. Version date: May 19, 2020.
12 SPRAVATO™ Product Monograph. Janssen Inc. Version date: May 19, 2020.
Social Publisher Accused of Locking Accounts of Jewish users for Star-of-David Profile Pics Las Vegas, Nevada – Parler, the People-driven social platform, took the occasion of Twitter being accused of locking the accounts of multiple Jewish users who featured images of the Star of David in their profile pictures, to voice its support for users displaying the Star of David, as well as other religious symbols, as symbols of love. According to stories in the Jerusalem Post, Israel National News, and The Yeshiva World, Twitter said the accounts’ displays of “hateful imagery” had violated the publishers’ Terms of Service.
According to the Jerusalem Post, holders of the locked accounts received the following message from the social media publisher: “We have determined that this account violated the Twitter Rules. Specifically for: Violating our rules against posting hateful imagery. You may not use hateful images or symbols in your profile image or profile header. As a result, we have locked your account."
Users were reportedly told to delete the images in order for their accounts to be restored.
The images in question ranged from a white Star of David in a graffiti style, to a superimposition of the modern blue star on the flag of Israel spliced with the yellow star Jews were forced to wear by the Nazis, to a montage of yellow stars. “The Star of David has been for almost two centuries a symbol of Judaism and Jewish identity for a people who were stateless,” said Parler Strategic investor Jeffrey Wernick. “For me as a Jew, it symbolizes my love for Judaism, which does not conflict in any way with my love for my nation and my love for humanity. To designate it, if the allegations are true, as a hateful image, is not only an act of hate but also likely libelous and slanderous. The desire to remove a symbol of my Jewish identity as “hateful imagery” is, to me, no different than the desire to remove me as hateful just because I am Jewish. And this is true whether I display it physically or not.” The Star of David has no official biblical authority, but became an important symbol of Jewish people living in the diaspora, and was universally adopted as a symbol of the Jewish People hundreds of years ago. The Star took on even greater significance as a symbol of heroism and sacrifice following the Holocaust and the founding of Israel as a Jewish State.
Twitter has a checkered history concerning anti-semitism. In 2015, the publisher allowed #killalljews to trend on its site. The hashtag is still searchable on Twitter. More recently, the publisher allowed #JewishPrivilege to trend, and the hashtag attracted many anti-semitic tweets.
Parler was founded in 2018 and has over 2.7 million users. The platform is committed to free speech, does not mine or sell user data, and does not censor content based on politics or ideology. Parler continues to stand with the People and against Technocronyism.
Nexelis Acquires Integrated Bioanalytical CRO AIT Bioscience
LAVAL, QC and INDIANAPOLIS, July 22, 2020 /CNW Telbec/ - Nexelis, a portfolio company of Ampersand Capital Partners and a leading provider of advanced assay development and laboratory testing services in the infectious, oncologic, and metabolic diseases fields, is pleased to announce its acquisition of AIT Bioscience.
Located in Indianapolis and founded 25 years ago, AIT Bioscience is an integrated bioanalytical laboratory with LC-MS and immunoassay testing capabilities which operates a paperless FDA-inspected facility supported by state-of-the-art electronic systems.
Commenting on the news, Benoit Bouche, Nexelis President and Chief Executive Officer said, "this is our fourth acquisition since 2018 and we are excited for AIT Bioscience to join the Nexelis growth story. AIT Bioscience has a scientifically strong team and operates within a geography that we see as an attractive location for future growth. AIT Bioscience's advanced testing capacity will help Nexelis further bolster its service offering in the bioanalytical segment and maintain competitive lead and turnaround times."
Tim McGrath, Nexelis' Chief Operating Officer who will oversee the Indianapolis operations, added, "I am happy and proud to have the responsibility to lead this new addition to Nexelis. This is an opportunity for me to work with experienced individuals, some of whom I have known for years. I am also excited to add large molecule mass spectrometry as a new service offering at Nexelis as this is a growing area where we now offer unique and specialized expertise."
The acquisition of AIT continues what has been a busy year at Nexelis. The company acquired Belgium-based immunogenicity and immune-oncology specialist ImmunXperts in March and has initiated a number of strategic partnerships to support the development of COVID-19 and other vaccines and biologics with global pharmaceutical companies and leading institutions such as the Bill and Melinda Gates Foundation and CEPI.
About Nexelis
With unrivaled expertise in immunology, and operating sites in North America (East and West Coast) and Europe, Nexelis is a leading provider of assay development and advanced laboratory testing services in the infectious diseases, metabolic diseases, and oncology fields. Our versatile team of scientists, working with our advanced technology platforms, were instrumental in the development, qualification, validation, and large-scale sample testing of assays that supported the FDA filing of almost 100 new molecular entities, including blockbuster vaccines, anti-viral drugs, and immunotherapy, gene and cell therapy products. For more information, please visit www.nexelis.com
About Ampersand Capital Partners
Founded in 1988, Ampersand is a middle-market private equity firm dedicated to growth-oriented investments in the healthcare sector. With offices in Boston and Amsterdam, Ampersand leverages its unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of our core healthcare sectors, including Brammer Bio, Confluent Medical, Genewiz, Genoptix, Talecris Biotherapeutics, and Viracor-IBT Laboratories. For more information, please visit www.ampersandcapital.com
SOURCE Nexelis
TRAIN IT RIGHT NEWSLETTER
Sign Up and get a free 7 day Train it Right HIIT Program!
